Paion AG
(FRA:PA8) will release the fourth quarter earnings for 2007 on March 3.
Based in Aache,
Germany, the
biopharmaceutical company, Paion AG is engaged in the provision of drugs to
treat strokes, problems in relation to the central nervous system and other
thrombotic diseases. The company’s
primary activity is to advance drug candidates, purchased and licensed
in-house, through clinical development phases and regulatory approval
processes. The company’s main product is
Desmoteplase. It is a plasminogen
activator which is used for the treatment of acute ischaemic strokes.
The company operates on a global basis through a partnership
with Forest Labs and Lundbeck.
PAION Deutschland GmbH is a wholly owned subsidiary of Paion
AG.
For more Earnings related events or to post your own events,
visit:
http://events.finditt.com/Events_list.aspx?catid=13
